Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of
rapamycin (mTor) pathway plays a role on the development and the lymphatic-vascular
organisations.
The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.
Phase:
Phase 3
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain